Baird Cuts Elevance Health Stock Price Target

Research firm cites concerns about the health insurance provider's outlook

Apr. 16, 2026 at 1:38pm

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up image of heavy, industrial banking machinery and mechanisms in shades of steel gray, bronze, and black, conveying a sense of institutional power and economic infrastructure.An extreme close-up of the complex inner workings of the financial system reflects the institutional forces shaping the outlook for health insurance providers.Indianapolis Today

Investment bank Robert W. Baird has lowered its price target for Elevance Health (NYSE: ELV) stock from $340 to $317, maintaining a 'neutral' rating on the shares. The analysts cited a more pessimistic forecast for the health insurance company's performance.

Why it matters

Elevance Health is one of the largest health benefits providers in the U.S., so changes to its stock price target by major research firms can impact investor sentiment and the company's valuation.

The details

In a research report, Baird analysts dropped their price target on Elevance Health shares from $340 to $317 while keeping a 'neutral' rating on the stock. The firm said its more cautious outlook is based on a revised forecast for the company's financial performance.

  • The new price target was issued on Wednesday, April 16, 2026.

The players

Robert W. Baird

An investment banking and asset management firm that provides research coverage on Elevance Health.

Elevance Health

A major U.S. health benefits company that provides medical and specialty health plans for individuals, employers, and government programs.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching to see if Elevance Health's stock price reacts to the new, lower price target from Baird. The company's next earnings report, scheduled for late January 2027, will also be closely monitored for signs of the performance issues cited by the research firm.

The takeaway

This downgrade from a major research firm highlights the challenges facing the health insurance industry, as companies navigate rising costs, regulatory changes, and evolving consumer preferences. Elevance Health's ability to navigate these headwinds will be crucial to its future stock performance.